MAP3K8 and non-small cell lung carcinoma: Other clinical trials of osimertinib as a second line of treatment for T790M-positive advanced NSCLC, such as AURA2 (Goss et al. 2016), AURA extension (Yang et al. 2017) and a pooled analysis of AURA2/AURA extension trials (Ahn et al. 2019) have also reported a prolonged median PFS of 9.9–12.3 months in overall population.